ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO006

TNFR-1, TNFR-2, and KIM-1 Plasma Concentrations After COVID-19 and Association With Kidney Function

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Chan, Lili, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Anandakrishnan, Nanditha, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Saha, Aparna, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Defronzo, Stefanie, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Mosoyan, Gohar, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Meliambro, Kristin, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Wisnivesky, Juan, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Nadkarni, Girish N., Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Stapleton, Sharon, Renalytix, New York, New York, United States
  • Fleming, Fergus, Renalytix, New York, New York, United States
  • Coca, Steven G., Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Azeloglu, Evren U., Icahn School of Medicine at Mount Sinai, New York, New York, United States
Background

Biomarkers TNFR1, TNFR2, and KIM1 are associated with progression of kidney disease. These biomarkers have not been evaluated in patients who have recovered from COVID-19.

Methods

Patients who had COVID-19 and recovered were followed longitudinally at an outpatient clinic with labs and surveys as part of the Mount Sinai Post-COVID clinic. Blood was sent for creatinine at baseline and 6 month follow up visit. We measured plasma TNFR1, TNFR2, and KIM-1 from the first post-COVID visit via Renalytix’ proprietary multiplex assay. eGFR was calculated using the 2021 CKD-EPI formula.

Results

450 COVID survivors had serum creatinine values measured at baseline (222±89 days post-COVID) and 6 month (419±97 days post-COVID) follow up. The average age of patients was 50±14 years, 62% were female, 60% were white, and 17% were Black. 23% were hospitalized, 4% required ICU admission, and 2% of patients reported AKI. eGFR at the baseline visit was 94±21 and at 6-months was 96±22 ml/min/1.73m2. At the baseline visit, KIM-1, TNFR-1, and TNFR-2 levels were highest in patients who were hospitalized and had AKI (Figure 1a) and concentrations of all three were associated with lower eGFR 6 months later (Figure 1b).

Conclusion

Severity of illness during COVID is associated with higher levels of plasma TNFR1, TNFR2, and KIM1 several months after recovery. The degree of biomarker elevation post-COVID was associated with lower kidney function more than 1 year post-COVID.

Funding

  • Commercial Support